Discussion about this post

User's avatar
P K's avatar

Hey CQ,

I just wanted to take a moment to express my gratitude for your latest article on valuing companies using a reverse DCF analysis. Without a doubt, it’s one of your best in my opinion! As always, the quality and depth of your content are unmatched, and I can't thank you enough for sharing your expertise with us.

I know I’ve said this before but it’s worth repeating that you have a true gift for teaching, my friend. The way you break down complex concepts into easily digestible pieces is simply remarkable. Your ability to make even the most daunting topics approachable and understandable is something I truly admire.

But it's not just the knowledge you impart that makes your articles stand out. Your writing style is engaging, relatable, and very enjoyable. You have a knack for making even the driest subject matter entertaining, and I find myself eagerly devouring each word you write.

So, thank you, CQ, for your exceptional work. I appreciate the time and effort you put into crafting such informative and engaging articles. You've made a genuine impact on me and countless others who have had the privilege of reading your work.

Keep up the fantastic work, and I'm eagerly looking forward to your next article!

Warmest regards,

Expand full comment
Justin's avatar

Hello

Thank you for posting this article - it’s excellent. I’m still trying to wrap my head around it but a few of beginner’s questions for you:

1. Why do you use the gdp growth as the long term in perpetuity growth rate?

2. With respect to the targeted expected return e.g of 9% - just checking this means the expected growth in share price based on number of current shares outstanding? (Ie it doesn’t take into account dividends etc).

3. Finally - in the final apple example - just want to confirm we are looking at the fcf growth rate the market is pricing in for the 9% return (share price growth) we are hoping to achieve as an investor.

That’s it. Thank you for your help

Expand full comment
82 more comments...

No posts